NCT06395402 - 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

May 3, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions

Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2

Interventions

DRUG

Lutetium Lu 177 dotatate therapy

LUTATHERA is an FDA approved radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumor (GEP-NET). This radiopharmaceutical binds to somatostatin receptors, which are overexpressed on GEP-NET cells, and subsequently delivers beta particle radiation to the tumor cells.

Trial Locations (1)

52242

RECRUITING

Holden Comprehensive Cancer Center at the University of Iowa, Iowa City